Equities

Audientes A/S

AUDNTS:AKT

Audientes A/S

Actions
  • Price (DKK)0.019
  • Today's Change0.002 / 14.46%
  • Shares traded525.10k
  • 1 Year change-90.76%
  • Beta--
Data delayed at least 15 minutes, as of Sep 23 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Audientes A/S is a Denmark-based company operating in the global hearing aid market. The company is a developer of the self-fitting hearing aid, which is dedicated to be rolled out in the Indian market and the United States over-the-counter (OTC) and other markets. Audientes' purpose is to help people who suffer from disabling hearing loss but cannot afford to buy conventional hearing aids available on the market.

  • Revenue in DKK (TTM)40.00k
  • Net income in DKK-11.82m
  • Incorporated2014
  • Employees5.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Audientes A/S40.00k-11.82m3.81m5.00--1.09--95.19-0.1409-0.14090.00030.01740.0026-0.19880.06453,636.36-75.28-47.21-216.96-64.671,697.50---29,550.00-4,172.600.1998-14.400.4113--1,502.53--44.98------
Qlife Holding AB75.06k-93.36m3.82m7.00------50.84-421.32-421.320.1965-12.310.00122.320.32574,750.00-145.74---322.68---16,077.19---124,388.60--0.1026-10.26-----98.64---71.74------
Medimi AB2.75m-8.98m5.54m6.00--1.09--2.01-0.0157-0.01570.00470.00720.30950.91452.27696,481.70-101.01-81.87-126.70-93.9340.844.06-326.40-840.932.52-46.180.279--75.13280.697.52------
Magnasense AB23.04k-27.27m7.64m14.00------331.32-1.77-1.770.0013-0.31830.0005--0.00912,500.00-64.04---76.03--100.00---118,334.30-----7.031.47---94.61--83.55------
VibroSense Dynamics AB1.40m-5.05m10.83m----1.29--7.72-0.3802-0.38020.11280.49790.1519-0.44358.40---54.65-49.44-65.05-56.99116.6994.64-359.70-466.015.83------17.5029.39-3.18--32.90--
S2Medical AB (publ)6.96m-1.23m12.22m17.00--0.8062--1.76-0.0193-0.01930.03330.02730.33560.29265.53621,550.00-5.91-65.16-14.21-101.5089.4565.03-17.62-220.190.43290.5410.00--49.2736.0522.91---14.81--
Perpetua Medical AB (publ)4.16m-5.59m12.25m0.00--1.80--2.95-0.1276-0.12760.07950.0950.407416.136.19---54.70-83.52-74.20-102.19-65.03-70.52-134.27-250.306.39--0.00---1.7657.204.63--8.89--
Level Bio AB (publ)15.95m-8.02m13.36m13.00--4.23--0.8373-0.1921-0.19210.38220.07571.294.989.811,863,894.00-65.05-6.39-105.55-10.512.57---50.26-4.090.6867-596.550.00---23.107.83-326.08---4.64--
Chordate Medical Holding AB (publ)739.51k-18.32m15.42m3.00--1.13--20.86-41.97-41.971.6721.160.0363-0.7463.53374,390.00-90.02-91.98-110.15-122.85219.20209.52-2,477.25-3,295.752.34--0.00--799.630.6511-4.45------
Invent Medic Sweden AB4.43m-5.29m18.15m9.00--5.65--4.10-0.1939-0.19390.16130.05660.60842.314.34841,046.30-72.67-97.56-133.97-121.0677.4377.16-119.45-490.980.3951-12.430.2703--115.97177.5328.77---22.61--
Miris Holding AB (publ)11.40m-6.19m18.80m10.00--3.68--1.65-0.2092-0.20920.36410.02710.8240.11177.251,732,100.00-44.74-59.61-95.35-111.0897.8386.68-54.30-103.610.7091-8.080.0903---17.192.53-20.86------
Data as of Sep 23 2024. Currency figures normalised to Audientes A/S's reporting currency: Danish Krone DKK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.